Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

METHYLPREDNISOLONE

All products: general benefit

Other products in the same Health Canada class (H02AB) — coverage varies; not interchangeable

  • Dexamethasone (Decadron): general benefit, Not a benefit
  • Dexamethasone (Decadron): general benefit, Not a benefit
  • Hydrocortisone (Cortef): general benefit, Listing status unconfirmed
  • Prednisolone (Pediapred Oral Liquid): general benefit, Not a benefit
  • Prednisone (Winpred): general benefit, Not a benefit
  • Triamcinolone acetonide (Kenalog-40): general benefit

2 more in the class list below

Medrol · DIN 00030988 · 4mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Medrol · DIN 00030988 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2006-01-10 · brand MEDROL · ATC H02AB04 METHYLPREDNISOLONE · form Tablet · route Oral · ingredients METHYLPREDNISOLONE 4 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Medrol: Formulary list price $0.5465/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5465 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1397 · Verify on the e-Formulary ↗ (DIN 00030988)

Source record
DIN 00030988: Medrol Raw flags: sec3=Y Item: 680400014; group id 715; item number 1767; lccId None; manufacturer id PFI Source form: Tab; strength: 4mg Recorded listing: General benefit Source prices (unrounded): $0.5465; ministry $0.5465 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00030988 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1397
Shortage status: resolved shortage (ended 2024-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00030988
Shortage record checked 2026-09-13T08:10:21.292534+00:00

METHYLPREDNISOLONE ACETATE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (H02AB) — coverage varies; not interchangeable

  • Dexamethasone (Decadron): general benefit, Not a benefit
  • Dexamethasone (Decadron): general benefit, Not a benefit
  • Hydrocortisone (Cortef): general benefit, Listing status unconfirmed
  • Prednisolone (Pediapred Oral Liquid): general benefit, Not a benefit
  • Prednisone (Winpred): general benefit, Not a benefit
  • Triamcinolone acetonide (Kenalog-40): general benefit

2 more in the class list below

Depo-Medrol · DIN 00030759 · 40mg/mL · injection suspension-1mL Pk

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Depo-Medrol · DIN 00030759 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2004-01-08 · brand DEPO-MEDROL · ATC H02AB04 METHYLPREDNISOLONE · form Suspension · route Intramuscular, Intrasynovial, Intralesional, Intra-articular · ingredients METHYLPREDNISOLONE ACETATE 40 MG/ML · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Depo-Medrol: Formulary list price $6.8762/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8762 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1134 · Verify on the e-Formulary ↗ (DIN 00030759)

Source record
DIN 00030759: Depo-Medrol Raw flags: sec3=Y Item: 680400025; group id 716; item number 1768; lccId None; manufacturer id PFI Source form: Inj Susp-1mL Pk; strength: 40mg/mL Recorded listing: General benefit Source prices (unrounded): $6.8762; ministry $6.8762 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00030759 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1134
Shortage status: anticipated shortage (last updated 2026-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00030759
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Depo-Medrol · DIN 00030767 · 80mg/mL · injection suspension-1mL Pk

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Depo-Medrol · DIN 00030767 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2004-03-16 · brand DEPO-MEDROL · ATC H02AB04 METHYLPREDNISOLONE · form Suspension · route Intrasynovial, Intra-articular, Intralesional, Intramuscular · ingredients METHYLPREDNISOLONE ACETATE 80 MG/ML · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Depo-Medrol: Formulary list price $13.1816/unit (unit not stated in source; not the patient's cost)

Ministry pays: $13.1816 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=789 · Verify on the e-Formulary ↗ (DIN 00030767)

Source record
DIN 00030767: Depo-Medrol Raw flags: sec3=Y Item: 680400024; group id 716; item number 1769; lccId None; manufacturer id PFI Source form: Inj Susp-1mL Pk; strength: 80mg/mL Recorded listing: General benefit Source prices (unrounded): $13.1816; ministry $13.1816 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00030767 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=789
Shortage status: resolved shortage (ended 2026-03-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00030767
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Depo-Medrol · DIN 01934325 · 100mg/5mL · injection suspension-5mL Pk

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Depo-Medrol · DIN 01934325 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2006-05-03 · brand DEPO-MEDROL · ATC H02AB04 METHYLPREDNISOLONE · form Suspension · route Intrasynovial, Intra-articular, Intramuscular, Intralesional · ingredients METHYLPREDNISOLONE ACETATE 20 MG/ML · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Depo-Medrol: Formulary list price $15.3767/unit (unit not stated in source; not the patient's cost)

Ministry pays: $15.3767 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18988 · Verify on the e-Formulary ↗ (DIN 01934325)

Source record
DIN 01934325: Depo-Medrol Raw flags: sec3=Y Item: 680400026; group id 716; item number 1770; lccId None; manufacturer id PFI Source form: Inj Susp-5mL Pk; strength: 100mg/5mL Recorded listing: General benefit Source prices (unrounded): $15.3767; ministry $15.3767 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01934325 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18988
Shortage status: resolved shortage (ended 2025-10-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01934325
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, HYDROCORTISONE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:04 Corticosteroids

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

PREDNISOLONE SODIUM PHOSPHATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 6.7mg/5mL · O/L

PREDNISONE

· 7 products · General benefit (5), Listed, not a benefit (2) · strengths: 1mg, 5mg, 50mg · Tab

TRIAMCINOLONE ACETONIDE

· 3 products · General benefit · strengths: 40mg/mL, 50mg/5mL, 200mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

TRIAMCINOLONE HEXACETONIDE

· 1 products · Limited Use, codes 580 · strengths: 20mg/mL · 1mL-Amp Pk

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk

FLUTICASONE FUROATE

· 2 products · General benefit · strengths: 100mcg, 200mcg · Blister Pd Inh-30 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 4 more
Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: endocrine disorders
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. HYDROCORTISONE · General benefit (6), Temporary benefit (1), Listed, not a benefit (2) 1 Indications CORTEF (hydrocortisone) is indicated for: • Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; nonsuppurative thyroiditis; hypercalcemia associated with cancer. PM: https://pdf.hres.ca/dpd_pm/00082414.PDF; date OCT 20, 2025; DIN 00030910; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. INDICATIONS Medrol (methylprednisolone) is indicated for: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. https://pdf.hres.ca/dpd_pm/00080809.PDF PM date: 2025-06-13 Source product: MEDROL; DIN 00030988; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. INDICATIONS DEPO-MEDROL (methylprednisolone acetate) is indicated for: A. FOR INTRAMUSCULAR ADMINISTRATION When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL (methylprednisolone acetate) is indicated as follows: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice, synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. https://pdf.hres.ca/dpd_pm/00080840.PDF PM date: 2025-06-19 Source product: DEPO-MEDROL; DIN 00030759; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.